BOLT
Bolt Biotherapeutics, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.35
P/S
1.23
EV/EBITDA
-0.63
DCF Value
$-116.14
FCF Yield
-421.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
80.6%
Operating Margin
-450.1%
Net Margin
-433.7%
ROE
-92.5%
ROA
-58.8%
ROIC
-67.7%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $2.5M | $-6.6M | $-3.84 |
| FY 2025 | $7.7M | $-33.4M | $-17.85 |
| Q3 2025 | $2.2M | $-7.1M | $-3.72 |
| Q2 2025 | $1.8M | $-8.6M | $-4.46 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.86
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.